Download MendeleyDiscovery and characterization of novel allosteric FAK inhibitors.
Iwatani, M., Iwata, H., Okabe, A., Skene, R.J., Tomita, N., Hayashi, Y., Aramaki, Y., Hosfield, D.J., Hori, A., Baba, A., Miki, H.(2013) Eur J Med Chem 61: 49-60
- PubMed: 22819505
- DOI: https://doi.org/10.1016/j.ejmech.2012.06.035
- Primary Citation of Related Structures:
4EBV, 4EBW - PubMed Abstract:
Focal adhesion kinase (FAK) regulates cell survival and proliferation pathways. Here we report the discovery of a highly selective series of 1,5-dihydropyrazolo[4,3-c][2,1]benzothiazines that demonstrate a novel mode of allosteric inhibition of FAK. These compounds showed slow dissociation from unphosphorylated FAK and were noncompetitive with ATP after long preincubation. Co-crystal structural analysis revealed that the compounds target a novel allosteric site within the C-lobe of the kinase domain, which induces disruption of ATP pocket formation leading to the inhibition of kinase activity. The potency of allosteric inhibition was reduced by phosphorylation of FAK. Coupled SAR analysis revealed that N-substitution of the fused pyrazole is critical to achieve allosteric binding and high selectivity among kinases.
Organizational Affiliation:
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
